Search

Your search keyword '"Montefiori, David"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Montefiori, David" Remove constraint Author: "Montefiori, David" Publisher cold spring harbor laboratory Remove constraint Publisher: cold spring harbor laboratory
65 results on '"Montefiori, David"'

Search Results

1. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies

2. A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals

3. SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition

4. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

5. Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.

6. Development of LIBRA-seq for the Guinea Pig Model System as a Tool for the Evaluation of Antibody Responses to Multivalent HIV-1 Vaccines

7. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera

8. Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines

10. Focusing antibody responses to the fusion peptide in rhesus macaques

11. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

12. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

13. Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in Humans

14. Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques

15. Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

16. Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19

17. Mutation-Guided Vaccine Design: A Strategy for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction

18. A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies

19. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

20. Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism

21. A Bivalent Omicron-containing Booster Vaccine Against Covid-19

23. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike

24. CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer

25. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

26. Vertical HIV-1 transmission in the setting of maternal broad and potent antibody responses

27. Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

28. Mapping SARS-CoV-2 antigenic relationships and serological responses

30. Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation

31. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization

32. Myeloid cell-driven nonregenerative pulmonary scarring is conserved in multiple nonhuman primate species regardless of SARS-CoV-2 infection modality

33. Persistent Immunogenicity of Integrase Defective Lentiviral Vectors delivering membrane tethered Native-Like HIV-1 Envelope Trimers

34. Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

35. Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation

36. The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease

37. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

38. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

39. Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles

40. Changes at V2 apex of HIV-1 Clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

41. Effective prophylaxis of COVID-19 in rhesus macaques using a combination of two parentally-administered SARS-CoV-2 neutralizing antibodies

42. Frequent development of broadly neutralizing antibodies in early life in a large cohort of HIV-infected children

43. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

44. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

45. SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

46. SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

47. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

48. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

49. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM

50. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

Catalog

Books, media, physical & digital resources